&lt;p&gt;Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study&lt;/p&gt;

Yuan, Guosheng; Cheng, Xiangdong; Li, Qi Rong; Zang, Meirong; Huang, Wei; Fan, Wenzhe; Wu, Tao; Ruan, Jian; Dai, Weiyu; Yu, Wenxuan; Chen, Mian; Guo, Yabing; Hu, Xiaoyun; Chen, Jinzhang

doi:10.2147/ott.s286169

Cited by 36 publications

(26 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main reason might be that lenvatinib plus an immune checkpoint inhibitor (camrelizumab) enhanced the anticancer efficacy, as lenvatinib could alleviate hypoxia and remodel the immunosuppressive tumour environment. Additionally, the median OS in our study was obviously longer than that reported by Yuan G, who conducted a multicentre retrospective study and found that the median OS was 14.8 months in patients with PVTT treated with camrelizumab combined with apatinib (Yuan et al, 2020). These could be due to that: 1) DEB-TACE are developed for loading and slowly releasing cytotoxic drugs into the tumour, and they also act as embolization agents to block blood supply to hypervascular tumors and thereby more effectively killing cancer cells and inducing tumor necrosis compared with non-TACE.…”

Section: Discussioncontrasting

confidence: 71%

“…A multicentre phase 2 trial conducted by Xu J and his colleagues found that the combination therapy of camrelizumab plus apatinib in advanced HCC patients resulted in median progression-free survival in two cohorts of 5.7 and 5.5 months, and the associated 12 months survival rates were 74.7 and 68.2%. Recently, Yuan G et al showed that camrelizumab plus apatinib could achieve a promising outcome in advanced HCC patients with portal vein tumour thrombus (PVTT) ( Yuan et al, 2020 ). There were also many studies showed encouraging antitumor activity and acceptable toxicity in patients with advanced non-small-cell lung cancer (NSCLC) and esophageal squamous cell carcinoma treated with camrelizumab plus apatinib ( Yan et al, 2020 ; Zhou et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients

Liu

Zhang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Aim: This study aimed to report the efficacy and safety of trans-arterial chemoembolization (TACE) plus lenvatinib and camrelizumab in patients with advanced hepatocellular carcinoma (HCC).Methods: This retrospective study enrolled 22 patients with advanced HCC from March 2018 to December 2019. All the patients received comprehensive treatment with TACE plus lenvatinib followed by camrelizumab. Overall survival (OS) and progression-free survival (PFS) were calculated and analysed using the Kaplan-Meier method and log-rank test. Treatment response and adverse events (AEs) were also evaluated.Results: The objective response rate (ORR) and disease control rate (DCR) for the whole cohort were 68.2 and 100% at the first month and 72.7 and 95.5% at the third month, respectively. The median OS was 24 months (95% CI, 20.323–27.677 months), and the median PFS was 11.4 months (95% CI, 8.846–13.954 months). The majority of treatment-related adverse reactions were mild or moderate, except for 4 that developed to grade 3–4 (3 reactions of grade 3, 1 reaction of grade 4). No deaths or other serious adverse reactions occurred.Conclusion:Trans-arterial chemoembolization plus lenvatinib and camrelizumab shows good results incontrolling tumour progression and prolonging median OS in patients with advanced HCC.

show abstract

Section: Discussioncontrasting

confidence: 71%

Section: Introductionmentioning

confidence: 99%

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients

Liu

Zhang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…The incidence of grade 3 and above AE was 78.6% in the first-line treatment group and 76.7% in the second-line treatment group, which was consistent with previous reports. In addition, findings from retrospective study (84) confirmed that camrelizumab combined with apatinib yielded a promising outcome in patients with HCC involving portal vein tumor thrombus.…”

Section: Camrelizumab Combined With Apatinibmentioning

confidence: 77%

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges

et al. 2021

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumor in the world and its incidence is increasing in many countries. In recent years, with the deepening understanding of the immune and pathological mechanisms of HCC, immunotherapy based on the regulation of tumor immune microenvironment has become a new treatment choice for patients with HCC. Immune checkpoint inhibitors (ICIs) targeting programmed death protein-1, programmed death protein-ligand-1, or cytotoxic T-lymphocyte-associated antigen 4 are the most widely used. Instead of general immune-enhancing therapies, ICIs can reactivate anti-tumor immune responses by disrupting co-inhibitory T cell signaling. In this review, the research progress and existing problems of ICIs in the treatment of HCC in recent years are reviewed.

show abstract

“…Yuan and his colleagues found that camrelizumab and apatinib obtained a favorable outcome in patients with advanced HCC who developed tumor thrombus. 14 These promising results may be due to the normalization of the tumor microenvironment. The VEGF/VEGFR pathway plays an important role in the regulation of the tumor microenvironment immune status.…”

Section: Discussionmentioning

confidence: 99%

Multidisciplinary treatment of advanced hepatocellular carcinoma with severe arterioportal shunt: a case report

Luo

Song

et al. 2021

J Int Med Res

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer mortality globally. In addition, most patients present in advanced stages with limited curative treatment options. Therefore, multidisciplinary treatment is often warranted. Here, we report a patient with HCC and severe arterioportal shunt (APS) who was treated with a multidisciplinary approach comprising interventional radiology procedures, apatinib and camrelizumab. After treatment, the intrahepatic mass was stable, and a notable decrease in the number and size of lung lesions was observed. The patient achieved a long-term survival of more than 2 years. These data suggest that multidisciplinary treatments may be effective in the treatment of advanced HCC with severe APS.

show abstract

<p>Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study</p>

Cited by 36 publications

References 43 publications

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges

Multidisciplinary treatment of advanced hepatocellular carcinoma with severe arterioportal shunt: a case report

Contact Info

Product

Resources

About